Condition (MeSH)
Carcinoma, Large Cell
ClinicalTrials.gov lists 20 trials for Carcinoma, Large Cell or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Carcinoma, Large Cell itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Large Cell trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2022 | 2 |
| 2016 | 1 |
| 2014 | 1 |
| 2012 | 2 |
| 2011 | 4 |
| 2008 | 3 |
| 2006 | 2 |
| 2004 | 1 |
| 2003 | 2 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Large Cell trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Phase 4 | 2 |
| Observational | 1 |
| Expanded access | 1 |
How many Carcinoma, Large Cell trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 9 |
| Terminated | 6 |
| Withdrawn | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Large Cell trials? (14)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Ariad Pharmaceuticals | 2 |
| Maia Biotechnology | 2 |
| Pfizer | 2 |
| Pharmacyclics LLC. | 2 |
| Celgene | 1 |
Showing 5 of 14 sponsors.
Which drugs are being tested for Carcinoma, Large Cell? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cemiplimab | 2 |
| Brigatinib | 2 |
| 6-Thio-2'-Deoxyguanosine | 2 |
| (nab)-paclitaxel | 2 |
| CP 751,871 (Figitumumab) | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 3 |
| Docetetaxel | 2 |
| ZD6474, Vandetanib | 1 |
| Motexafin Gadolinium Injection | 1 |
| PF-02341066/PF-00299804 | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Large Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Disease progression | 498 | 2 |
| Pneumonia | 104 | 5 |
| Dyspnoea | 62 | 5 |
| Dehydration | 47 | 4 |
| Diarrhoea | 42 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Large Cell? (86)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study. | BMC cancer | 2023 | Yes |
| SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. | Lung cancer (Amsterdam, Netherlands) | 2020 | Yes |
| The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018 | Yes |
| Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). | Clinical lung cancer | 2018 | Yes |
| Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer. | Clinical lung cancer | 2017 | Yes |
Showing 5 of 86 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.